SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncolytics Biotech announced alignment with the FDA on a randomized…

ONCOLYTICS BIOTECH INC · 8-K filed Apr 27, 2026 at 08:16 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 27, 2026 at 08:16 ET

Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design for pelareorep in metastatic squamous cell carcinoma of the anal canal (SCAC), a rare cancer with no approved therapies post-first-line treatment. The study leverages strong prior data showing improved duration of response and survival versus standard of care.

  • FDA alignment achieved on pivotal randomized controlled trial for pelareorep in metastatic SCAC
  • Study targets post-standard-of-care population with no FDA-approved options
  • Prior data showed 15.5 vs 9.5 month median duration of response and 82% vs 45.7% 12-month survival vs standard of care
  • Trial design may support both accelerated and full approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access